CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
Minocycline Hydrochloride +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02297412
NCT02297412Phase 2Completed

Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial

Academic and Community Cancer Research United·interventional·Posted Nov 21, 2014·Updated Jan 31, 2022

In Brief

A Phase 2 clinical trial evaluating Minocycline Hydrochloride, Placebo, and 2 other interventions for Acute Pain and 2 related conditions. Completed, enrolled 47 participants across 12 sites.

Detailed Summary

This randomized pilot trial studies how well minocycline hydrochloride works in reducing chemotherapy-induced peripheral neuropathy and acute pain in patients with breast cancer undergoing treatment with paclitaxel. Drugs used in chemotherapy, such as paclitaxel, may cause damage to nerves that result in aches, pains, and tingling or numbness of fingers and toes. Minocycline hydrochloride may help lessen nerve damage from paclitaxel and improve the quality of life in breast cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 21, 2014
Enrollment StartNov 1, 2014
Primary CompletionJul 8, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.6 years ago

Interventions

Minocycline Hydrochloridedrug

Given PO

Placeboother

Given PO

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies